Seer to Present at the Cowen 41st Annual Healthcare Conference
Seer, a life sciences company listed on Nasdaq under the symbol SEER, will participate in the Cowen 41st Annual Healthcare Conference on March 3, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer, a life sciences company listed on Nasdaq under the symbol SEER, will participate in the Cowen 41st Annual Healthcare Conference on March 3, 2021. The management will engage in a fireside chat at 8:40 a.m. PT / 11:40 a.m. ET. A live webcast will be accessible on the company’s investor website, with an archived replay available post-conference. Seer focuses on enhancing scientific outcomes through its Proteograph™ Product Suite, designed for comprehensive proteomics analysis in a short time frame.
Details
News Market Reaction – SEER
The recorded move for SEER in the trading session of this news was -8.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating in the upcoming Cowen 41st Annual Healthcare Conference.
Seer’s management is scheduled to participate in a fireside chat on Wednesday, March 3 at 8:40 a.m. Pacific Time / 11:40 a.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.
About Seer
Seer™ is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. Seer is developing its Proteograph™ Product Suite, which is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. Seer designed the Proteograph to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution broadly available to life sciences researchers. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact
Carrie Mendivil
investor@seer.bio
Media Contact
Karen Possemato
pr@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.